Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Thromb Thrombolysis ; 50(2): 371-379, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32166540

RESUMO

Factor Xa (FXa) inhibitors are recommended for use in fixed doses without laboratory monitoring. However, prior studies reported the importance of establishing biomarkers representing anticoagulation intensity related to bleeding or thrombotic events. To test the hypothesis that prothrombin activation fragment 1 and 2 (F1 + 2), a non-specific marker of thrombin generation, could be altered during FXa inhibitor treatment in patients with atrial fibrillation. We conducted the study in two different clinical settings. First, the interrelations among biomarkers representing coagulation/fibrinolysis were investigated in 80 patients in an outpatient clinic. Second, these biomarkers were evaluated in 75 patients who underwent radiofrequency catheter ablation. Plasma concentration of FXa inhibitors was evaluated using an anti-FXa chromogenic assay (C-Xa). In the outpatient study, only F1 + 2 exhibited a significant and negative association with C-Xa (rS = - 0.315, p = 0.026), and 37% of the variance could be explained by C-Xa levels. F1 + 2 levels above the reference range (> 229 pmol/L) could be considered as a cut-off to identify poor patient compliance or under-dosing. In the peri-ablation study, increased F1 + 2 levels were associated with decline of C-Xa levels after periprocedural discontinuation of FXa inhibitors, which was greater in the rivaroxaban group than in the apixaban group. F1 + 2 showed modest and inverse association with plasma concentration of rivaroxaban and apixaban in patients with atrial fibrillation. Larger study to test the hypothesis that continued thrombin generation despite anticoagulation is associated with a heightened risk of clinical events is required.


Assuntos
Fibrilação Atrial/tratamento farmacológico , Monitoramento de Medicamentos , Inibidores do Fator Xa/uso terapêutico , Fragmentos de Peptídeos/sangue , Pirazóis/uso terapêutico , Piridonas/uso terapêutico , Rivaroxabana/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Fibrilação Atrial/sangue , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/cirurgia , Biomarcadores/sangue , Ablação por Cateter , Inibidores do Fator Xa/efeitos adversos , Feminino , Humanos , Masculino , Protrombina , Pirazóis/efeitos adversos , Piridonas/efeitos adversos , Rivaroxabana/efeitos adversos , Fatores de Tempo , Resultado do Tratamento
2.
J Thromb Thrombolysis ; 38(1): 105-14, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23928870

RESUMO

Warfarin is the most widely prescribed oral anticoagulant, but large interindividual variations exist in the dose required to achieve comparable therapeutic effects. Several clinical and genetic variables have been identified that influence warfarin dosing. However, interactions between genotype and nutrition remain uncertain in terms of dietary vitamin K intake. To investigate genotype-nutrient interactions in warfarin anticoagulation therapy, 202 consecutive outpatients (M/F = 142/60, mean age, 69 years) undergoing treatment with warfarin were enrolled. Prevalent single nucleotide polymorphisms in VKORC1 and CYP2C9 were genotyped, and dietary vitamin K intake during the week preceding the blood sampling was quantitatively estimated by a dietitian-assisted questionnaire. Patients were classified according to low, medium, or high vitamin K intake. The mean daily warfarin dose in subjects with a VKORC1-1639 A/A genotype was significantly smaller than that with a -1639A/G genotype (2.74 vs. 3.91 mg/day, respectively, p < 0.0001). Dose requirements did not differ between subjects with a CYP2C9 *1/*3 genotype versus a CYP2C9 *1/*1 genotype. In subjects with a variant VKORC1-1639 G allele, the mean daily warfarin dose was significantly attenuated by low vitamin K intake compared with medium and high intake after adjustment for covariates (3.4 vs. 5.0 vs. 4.0 mg/day, respectively, p = 0.028). No such genotype effects were observed in homozygous patients for the VKORC1-1639 A allele. The results of the present study suggest that the capacity of dietary vitamin K intake to influence warfarin dose requirements during anticoagulation therapy is VKORC1 genotype-dependent, at least in part.


Assuntos
Anticoagulantes/administração & dosagem , Interações Alimento-Droga/genética , Genótipo , Polimorfismo de Nucleotídeo Único , Vitamina K Epóxido Redutases/genética , Vitamina K/administração & dosagem , Varfarina/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/efeitos adversos , Citocromo P-450 CYP2C9/genética , Citocromo P-450 CYP2C9/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Farmacogenética/métodos , Vitamina K/efeitos adversos , Vitamina K Epóxido Redutases/metabolismo , Varfarina/efeitos adversos
3.
J Cardiol Cases ; 21(3): 101-103, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32153683

RESUMO

Coronary sinus ostial atresia is rare and usually not clinically relevant, but it should be noted in cases of cardiac resynchronization therapy. A rare case of successful left ventricular lead implantation for cardiac resynchronization therapy via the left superior vena cava in a patient with coronary sinus ostial atresia is reported. The persistent left superior vena cava associated with these cases tends to be smaller than usual in its diameter and difficult to identify, since the direction of venous drainage is reversed. Therefore, in the present case, it was useful to use a small-diameter, soft inner catheter as a guiding catheter to perform selective imaging and avoid vascular injury. In addition, it appeared to be important to plan the surgical strategy using prior imaging information, since it would be difficult to obtain the backup needed for lead insertion. 〈: Learning objective: Cardiac resynchronization therapy via the left superior vena cava with coronary sinus ostial atresia is generally possible without problems if prior imaging information is available, such as three-dimensional computed tomography and the venous phase of coronary angiography. It is important to determine whether there is a persistent left superior vena cava before the procedure. Thromboprophylaxis remains controversial in this situation.〉.

4.
Dis Markers ; 2016: 7650976, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26880856

RESUMO

Atrial fibrillation (AF) is the most common cardiac arrhythmia, but its proarrhythmic mechanism remains to be elucidated. Glutamate (Glu) and taurine (Tau) are present in the myocardium at substantially higher concentrations than in the plasma, suggesting their active role in myocardium. Here, we tested the hypothesis that the metabolism of Glu and Tau is altered in association with the generation of reactive oxygen species (ROS) in patients with AF. Fifty patients with paroxysmal AF and 50 control subjects without a history of AF were consecutively enrolled. Circulating Glu and Tau levels were measured and correlations between Glu/Tau and ROS levels were examined. Glu/Tau content was significantly higher in patients with AF versus controls (Glu: 79.2 ± 23.9 versus 60.5 ± 25.2 nmol/L; Tau: 78.8 ± 19.8 versus 68.5 ± 20.8 nmol/L; mean ± standard deviation (SD), p < 0.001 for both). Glu/Tau levels also showed an independent association with AF by multiple logistic regression analysis. Glu and Tau levels both showed significant positive associations with plasma hydroperoxide concentrations. These data suggest a novel pathophysiological role of Glu and Tau in association with ROS production in paroxysmal AF, providing new insights into the elevated amino acid content in cardiac disease.


Assuntos
Fibrilação Atrial/metabolismo , Ácido Glutâmico/sangue , Espécies Reativas de Oxigênio/sangue , Taurina/sangue , Idoso , Fibrilação Atrial/patologia , Feminino , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade
5.
Jpn J Physiol ; 53(3): 173-80, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-14529578

RESUMO

The objective of the present study was to investigate the differential activation of protein kinase C between ischemic (IPC) and pharmacological preconditioning (PPC) in the rabbit heart. Control, IPC, diazoxide (Diaz), and chelerythrine (Chel)+IPC groups underwent prolonged coronary artery occlusion (CAO) for 30 minutes followed by 180 minutes' reperfusion (protocol I). In protocol II, sham, IPC-only, Diaz-only, and Chel+IPC-only groups did not undergo prolonged CAO. IPC was induced with 4 cycles of 5-min regional ischemia and 10-min reperfusion before prolonged CAO. Diaz (5 mg/kg) was administered 30 min before prolonged CAO. Chel (5 mg/kg) was administered 5 min before the IPC procedure. Infarct size was determined by tetrazolium staining. Assessment of protein kinase C (PKC) isoforms from a left ventricular (LV) sample was conducted by western blotting. Apoptosis in situ was determined by TUNEL assay. The infarction area in the IPC (11.6 +/- 1.0%) and Diaz (19.5 +/- 3.8%) groups was reduced significantly (p< 0.01, p< 0.05) relative to the control group (40.0 +/- 3.8%). The reduction by IPC was abolished by pretreatment with Chel. Apoptosis was significantly decreased (p< 0.01) in the IPC and diazoxide groups compared with the control and Chel+IPC groups (control: 4.78 +/- 0.56% vs. IPC: 2.00 +/- 0.38% vs. Diaz: 2.20 +/- 0.32% vs. Chel+IPC: 4.32 +/- 0.41%) and DNA laddering was attenuated in the IPC and Diaz groups. Membrane PKC-epsilon levels in the IPC and Diaz groups increased significantly relative to the control and Chel+IPC groups. Membrane PKC-epsilon levels in the IPC-only group showed greater increases than the Diaz-only and Chel+IPC-only groups. These findings suggest that whereas PPC suppresses apoptosis when diazoxide opens mitochondrial K(ATP) channels and then activates PKC-epsilon through ischemia-reperfusion, IPC activates PKC-epsilon in the particulate fraction prior to continuous ischemia-reperfusion. We concluded that the difference between IPC and PPC appears to consist in the difference in the timing of PKC-epsilon activation, though both IPC and PPC provide the cardioprotection in ischemia-reperfusion injury.


Assuntos
Condicionamento Psicológico , Diazóxido/farmacologia , Inibidores Enzimáticos/farmacologia , Coração/efeitos dos fármacos , Precondicionamento Isquêmico Miocárdico , Fenantridinas/farmacologia , Proteína Quinase C/metabolismo , Alcaloides , Animais , Benzofenantridinas , Cardiotônicos/farmacologia , Fragmentação do DNA , Sinergismo Farmacológico , Ativação Enzimática , Genoma , Hemodinâmica , Isoenzimas/metabolismo , Infarto do Miocárdio/patologia , Miocárdio/enzimologia , Miócitos Cardíacos , Coelhos , Função Ventricular Esquerda
7.
J Cardiol ; 50(1): 1-10, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17685024

RESUMO

OBJECTIVES: We tested our hypothesis that, in atrial flutter (AFL) dependent on the cavotricuspid isthmus (CTI), lower loop reentry is the common pathway route at the coronary sinus posterior site, and thus, dual loop reentry is a common circular pattern. METHODS AND RESULTS: We studied 25 patients with CTI-dependent AFL, 16 with chronic counterclockwise atrial flutter (CCW-AFL) and 9 with clockwise atrial flutter (CW-AFL) and determined the precise reentry circuitry, especially for conduction patterns around the coronary sinus orifice, using electroanatomical mapping. We measured post pacing interval and tachycardia cycle length during entrainment from sites within the flutter circuit. The coronary sinus anterior pacing site was within the AFL circuit in 16 of the 25 CCW-AFL patients, and in 6 of the 9 CW-AFL patients. Both the coronary sinus anterior and posterior sites were within the AFL circuit in 8 of 16 CCW-AFL and 8 of the 9 CW-AFL patients. Results of 3-dimensional activation mapping suggest that all of these patients have a dual loop reentry circuit, and that coronary sinus posterior conduction broke through the eustachian valve/ridge. CONCLUSIONS: Coronary sinus posterior conduction consisted of the flutter circuit and appeared to be critical for maintaining AFL.


Assuntos
Flutter Atrial/fisiopatologia , Sistema de Condução Cardíaco/fisiopatologia , Taquicardia por Reentrada no Nó Atrioventricular/fisiopatologia , Valva Tricúspide/fisiopatologia , Idoso , Mapeamento Potencial de Superfície Corporal , Ablação por Cateter , Técnicas Eletrofisiológicas Cardíacas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Taquicardia por Reentrada no Nó Atrioventricular/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA